Scarica l'app Stockscreener
66.88
0.78%
0.52
Dopo l'orario di chiusura:
65.53
-1.35
-2.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$66.36
Aprire:
$66.33
Volume 24 ore:
1.68M
Relative Volume:
0.84
Capitalizzazione di mercato:
$7.82B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
22.15
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
+2.72%
1M Prestazione:
-11.83%
6M Prestazione:
+13.70%
1 anno Prestazione:
+25.10%
Intervallo 1D:
$65.65
$67.31
Intervallo di 1 settimana:
$63.78
$68.00
Portata 52W:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
66.88 | 7.80B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Is Halozyme Therapeutics Inc. stock bottoming outCPI Data & Accurate Entry and Exit Point Alerts - newser.com
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? - sharewise.com
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
HALO: HC Wainwright & Co. Reiterates Buy Rating with $90 Target | HALO Stock News - GuruFocus
Leerink Partners Upgrades Halozyme Therapeutics (HALO) - Nasdaq
Leerink Partners upgrades Halozyme stock to Market Perform on lower Medicare exposure - Investing.com Nigeria
HALO Upgraded to Market Perform by Leerink Partners | HALO Stock News - GuruFocus
Halozyme Confirms Minimal Impact from Medicare Guidance - TipRanks
Halozyme Therapeutics issues statement on Medicare price negotiation guidance By Investing.com - Investing.com South Africa
Halozyme Therapeutics issues statement on Medicare price negotiation guidance - Investing.com
Halozyme Therapeutics (HALO) Stock Analysis: Robust Revenue Growth and Potential 18.56% Upside - DirectorsTalk Interviews
Janney Montgomery Scott LLC Sells 269,655 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
How to build a dashboard for Halozyme Therapeutics Inc. stockQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Oak Ridge Investments LLC Trims Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Castellan Group Has $832,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics To $80? - Forbes
Zacks Research Issues Negative Estimate for HALO Earnings - MarketBeat
What technical models suggest about Halozyme Therapeutics Inc.’s comebackWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Using data tools to time your Halozyme Therapeutics Inc. exitQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Heatmap analysis for Halozyme Therapeutics Inc. and competitors2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Tectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" Rating - MarketBeat
Key metrics from Halozyme Therapeutics Inc.’s quarterly data2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Portfolio - earlytimes.in
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current Valuation - Yahoo
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Could Halozyme’s (HALO) New COO Appointment Signal a Shift in Operational Strategy or Partnerships? - Sahm
Halozyme Appoints New Chief Operating Officer - The Globe and Mail
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer - MarketScreener
Halozyme (HALO) Appoints New Chief Operating Officer - GuruFocus
Halozyme names Cortney Caudill as COO - TipRanks
Halozyme Therapeutics appoints Cortney Caudill as chief operating officer - Investing.com
Halozyme Therapeutics, Inc. Announces Appointment of Cortney Caudill as Senior Vice President and Chief Operating Officer, Effective October 1, 2025 - MarketScreener
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Nasdaq
Pattern recognition hints at Halozyme Therapeutics Inc. upsideEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
FY2025 EPS Forecast for Halozyme Therapeutics Cut by Analyst - MarketBeat
How buybacks impact Halozyme Therapeutics Inc. stock valueWeekly Trade Summary & Technical Pattern Based Signals - newser.com
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stock2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme Announces Merger Agreement with Elektrofi - TipRanks
Halozyme Therapeutics says if deal is terminated under certain circumstances, co to pay Elektrofi reverse termination fee of $36 million - MarketScreener
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Research Analysts Set Expectations for HALO FY2026 Earnings - MarketBeat
Institutional scanner results for Halozyme Therapeutics Inc.2025 Top Gainers & Daily Price Action Insights - newser.com
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):